AMP Capital Investors Ltd decreased its holdings in MEDNAX Inc (NYSE:MD) by 54.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 56,118 shares of the company’s stock after selling 65,866 shares during the quarter. AMP Capital Investors Ltd owned about 0.06% of MEDNAX worth $2,999,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in MD. Nationwide Fund Advisors raised its position in MEDNAX by 9.7% in the 3rd quarter. Nationwide Fund Advisors now owns 513,389 shares of the company’s stock valued at $22,137,000 after purchasing an additional 45,472 shares during the last quarter. Principal Financial Group Inc. raised its position in MEDNAX by 0.7% in the 3rd quarter. Principal Financial Group Inc. now owns 398,057 shares of the company’s stock valued at $17,164,000 after purchasing an additional 2,665 shares during the last quarter. Sei Investments Co. raised its position in MEDNAX by 4.6% in the 3rd quarter. Sei Investments Co. now owns 107,871 shares of the company’s stock valued at $4,652,000 after purchasing an additional 4,763 shares during the last quarter. Advisor Group Inc. raised its position in MEDNAX by 41.9% in the 3rd quarter. Advisor Group Inc. now owns 8,361 shares of the company’s stock valued at $359,000 after purchasing an additional 2,468 shares during the last quarter. Finally, Rhumbline Advisers raised its position in MEDNAX by 9.5% in the 3rd quarter. Rhumbline Advisers now owns 207,559 shares of the company’s stock valued at $8,950,000 after purchasing an additional 17,987 shares during the last quarter. Hedge funds and other institutional investors own 98.53% of the company’s stock.
MEDNAX stock opened at $56.38 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.18 and a current ratio of 1.18. MEDNAX Inc has a 12 month low of $40.56 and a 12 month high of $69.89. The firm has a market cap of $5,315.39, a price-to-earnings ratio of 16.34, a PEG ratio of 1.40 and a beta of 0.26.
MEDNAX (NYSE:MD) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.87 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.83 by $0.04. MEDNAX had a net margin of 9.26% and a return on equity of 10.10%. The business had revenue of $910.82 million for the quarter, compared to analysts’ expectations of $884.55 million. During the same period in the prior year, the company posted $1.00 EPS. The business’s revenue for the quarter was up 9.6% on a year-over-year basis. research analysts predict that MEDNAX Inc will post 4.03 earnings per share for the current year.
In other news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $58.35, for a total transaction of $175,050.00. Following the transaction, the insider now directly owns 39,716 shares of the company’s stock, valued at approximately $2,317,428.60. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 2.40% of the company’s stock.
MD has been the subject of a number of analyst reports. Piper Jaffray Companies initiated coverage on shares of MEDNAX in a research report on Wednesday, December 13th. They set an “overweight” rating and a $58.00 price objective for the company. SunTrust Banks set a $55.00 price objective on shares of MEDNAX and gave the stock a “hold” rating in a research report on Thursday, December 21st. Zacks Investment Research upgraded shares of MEDNAX from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a research report on Tuesday, January 23rd. Stifel Nicolaus restated a “hold” rating and set a $56.00 price objective on shares of MEDNAX in a research report on Wednesday, January 24th. Finally, Mizuho set a $49.00 price objective on shares of MEDNAX and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $55.58.
WARNING: This piece was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://ledgergazette.com/2018/03/22/amp-capital-investors-ltd-trims-position-in-mednax-inc-md.html.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.